


Fusogenix

Fusogenic Liposomal Drug Delivery





Innovascreen Inc.

Innovascreen is an ideal partner for any Pharmaceutical or Biotech company engaged in early-stage research and development of novel therapeutics. With two proprietary platforms, the ASET Platform for early preclinical research and the Fusogenix Platform for drug delivery, Innovascreen has the tools to accelerate the drug development process. Whether combined with internal programs or partnered with external compounds, these platforms have the opportunity to add significant value to preclinical therapeutic opportunities.

The Fusogenix Platform for Drug Delivery

Current liposome technologies rely on fusion-inducing lipids or peptides that lead to liposome disruption rather than liposome-cell fusion. This can lead to systemic dispersion of the drug or alternatively, uptake into endosomes resulting in drug degradation. The Fusogenix system incorporates Innovascreen's proprietary fusion-associated small transmembrane (FAST) proteins. These FAST proteins mediate efficient liposome-cell fusion, bypassing the degradative endocytic entry pathway, releasing their contents directly into the cytoplasm. FAST-liposomes fuse to a broad range of cell types and have no inherent receptor-binding activity, making them compatible with emerging antibody- or peptide-based targeting technology.



Fusogenix liposomes bypass the endocytic pathway and deliver their cargo directly into the cytoplasm. Scanning electron microscopy shows Fusogenix liposome fusing with the plasma membrane of a breast cancer cell.

High magnification confocal microscopy image showing delivery of a green fluorescent dye (fluorescein) into a breast cancer cell (red) using Fusogenix liposomes. Our proprietary fusion platform increases the frequency of membrane fusion more than 80x compared to conventional liposomes.

Incorporation of FAST protein into Innovascreen's Fusogenix liposomes increases the frequency of membrane fusion more than 80x compared to conventional liposomes. Fusogenix has the opportunity to add value to a number of therapeutic categories that would benefit from encapsulation to increase efficacy including bioactive peptides, small molecules and RNAi.